You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. RECAL:A New Tool for Disease Detection and Biomolecular Imaging

    SBC: Photon Biosciences LLC            Topic: 400

    Project SummaryAbstract We envision developing a new ultrasensitive detection platform that combines a recombinant protein with a unique imaging media that results in a luminescent protein that is non bleaching and non blinkingThe excitation and emission wavelengths of this protein can be tuned with the choice of imaging media and span much of the visible and near infrared regions of the electroma ...

    SBIR Phase I 2018 Department of Health and Human Services
  2. Real-Time Salivary Testosterone and Extension to Mobile Application and Multiple Biomarker Quantification Capability

    SBC: OASIS DIAGNOSTICS CORPORATION            Topic: NIDA

    Program Director Principal InvestigatorLastFirstMiddleSloweyPaul DAbstract This phase I NIH SBIR proposal seeks support for an interdisciplinary partnership between Oasis Diagnosticsand Iowa State University who collaboratively seek to develop a novel tool that can measure and quantify levels of the sex hormone testosterone in saliva within minutes of collectionVerOFytestosteroneThe FDA has urged ...

    SBIR Phase I 2018 Department of Health and Human Services
  3. Development of an alpha-conotoxin RgIA analog as a novel, non-opioid therapeutic for chronic neuropathic pain

    SBC: KINETA, INC.            Topic: NIDA

    PROJECT SUMMARY The objective of this SBIR Phase I application is to select an optimized lead analog ofconotoxin RgIA to develop as a uniquenon opioid therapeutic for chronic neuropathic painRgIAa peptide derived from the predatory marine cone snail Conus regiusis an inhibitor of thenicotinic acetylcholine receptornAChRa novel genetically validated pain targetOur current lead candidateKCPpotently ...

    SBIR Phase I 2018 Department of Health and Human Services
  4. Development of a syringe/sonication device employed to administer DDFPe in the prehospital setting

    SBC: NUVOX PHARMA, L.L.C.            Topic: 101

    PROJECT SUMMARY ABSTRACT Clinical ChallengeIn acute traumain the civilian settinghemorrhage is the second most leading cause of deathIn the military settingof potentially preventable deaths are caused by hemorrhage due to traumaof civilian andof military mortality caused by traumatic hemorrhage occurs pre hospitalizationAdverse outcome in trauma patients during prehospital resuscitation is due to ...

    SBIR Phase I 2018 Department of Health and Human Services
  5. Novel Targeting of the S1P Receptor, S1P1, and Nox4 as Therapeutic Approaches in ARDS

    SBC: RESTORE THERAPEUTICS LLC            Topic: NHLBI

    PROJECT SUMMARYAcute Respiratory Distress SyndromeARDSis a devastating syndrome that afflicts more thanpatients in United States alone and has an unacceptably high mortality rate ofCurrently there are no therapies that address the loss of lung vascular barrier integrityvascular leakage and alveolar flooding that are critical features of ARDS pathobiologyThe PI was the first to demonstrate that sph ...

    STTR Phase I 2018 Department of Health and Human Services
  6. Preclinical studies of Selective and Orally Bioavailable Aurora B Inhibitors for the Treatment of AML

    SBC: SYNACTIX PHARMACEUTICALS, INC.            Topic: 102

    ABSTRACTThe Aurora Kinase FamilyAKFcomprises heavily pursued therapeutic targets for cancer because of their intimate involvement in cell division and tumor progressionNumerous therapeutic campaigns have been initiated against the AKFwith promising clinical successes emanating from strategies targeting either Aurora A or Aurora BHoweverthe US Food and Drug Administration has yet to approve a cance ...

    STTR Phase I 2018 Department of Health and Human Services
  7. Novel peptide drug conjugates for the treatment of triple-negative breast cancers: Direct anti-tumor activity and immuno-oncology preclinical studies.

    SBC: ONCOTHERAPY SOLUTIONS LLC            Topic: 102

    ABSTRACT Triple negative breast cancersTNBCsare clinically very aggressive tumors with standard chemotherapy the only therapeutic option for patients with such cancers but the response rates are low and the prognosis remains poorPrevious published studies show that LHRH receptor is detected inof biopsy specimens from patients with TNBC and could be used for delivery of cytotoxic agentsHerewe propo ...

    SBIR Phase I 2018 Department of Health and Human Services
  8. Synthetic Universal Flu Vaccine

    SBC: TRIA BIOSCIENCE CORP.            Topic: NCIRD

    Abstract Type A and B Influenza viruses cause severe seasonal epidemics and less frequent but more deadly pandemic infectionsVaccination provides the best protectionalthough serious problems are confronting the global Influenza marketVirus diversity and mutation rates necessitate the annual production of hundreds of millions of vaccines using antiquated egg based technologiesCompounding this is th ...

    SBIR Phase I 2018 Department of Health and Human Services
  9. Clinical mass spectrometry test for apolipoprotein C-III proteoforms

    SBC: Isoformix Inc.            Topic: 400

    PROJECT SUMMARY Only about dozen mass spectrometryMSprotein tests have been translated into clinical laboratories since the MALDI and ESI approaches were developed thirty years agoWhile the cost and complexity of these tests are important factors impeding their clinical adoptionnew content generated via proteoforms detection could provide the impetus for further development and translationOur rece ...

    SBIR Phase I 2018 Department of Health and Human Services
  10. Continuous emulsion digital PCR (cdPCR) for low-cost, rapid, near point-of-care genotyping of non-small cell lung cancer

    SBC: DropWorks, Inc.            Topic: 102

    PROJECT SUMMARY Genotyping of cancer has become the standard of carewhere specific mutations in cancer driving genes have been shown to indicate sensitivity or resistance to targeted treatmentsSampling of cell free DNAcfDNAin blood plasma could provide a non invasive means of performing this genotypingbut current methods are too complexslowdaysand expensivehundreds of dollarsto make use of this in ...

    STTR Phase I 2018 Department of Health and Human Services
US Flag An Official Website of the United States Government